Lyme Disease and Pregnancy by Alexander, James M. & Cox, Susan M.
Infectious Diseases in Obstetrics and Gynecology 3:256-261 (1995)
(C) 1996 Wiley-Liss, Inc.
Lyme Disease and Pregnancy
James M. Alexander and Susan M. Cox
Department of Obstetrics and Gynecology, University of Texas Southwaestern Medical Center, Dallas, TX
ABSTRACT
Lyme disease is the most commonly transmitted vector-borne disease in the United States, with
many regions ofthe country at risk. Like other spirochete-borne infections, Lyme disease progresses
in stages, making diagnosis in the early stages of the illness and prompt treatment important for
cure. An early diagnosis is made difficult by the less-than-ideal serologic tests and the varied
clinical presentations of the disease. Although Lyme disease has been reported in pregnancy, the
transmission rate to the fetus and potential harmful effects are largely unknown. This review
discusses the diagnosis, clinical course, and treatment of Lyme disease with an emphasis on the
pregnant patient. (C) 1996 Wiley-Liss, Inc.
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Yme disease, originally called Lyme arthritis,
was first recognized in 1975 based on observa-
tions of geographic clustering of affected children
in Lyme, CT. These children were thought to have
juvenile rheumatoid arthritis; however, an unusual
skin lesion, erythema chronicum migrans (ECM),
was often observed prior to the development of
arthritis. The clustering of cases along with the her-
aiding lesion suggested an infectious etiology of
Lyme disease. Furthermore, the cases were more
common in rural areas during the summer months,
suggesting an arthropod vector. Epidemiologic
studies of patients reporting ECM suggested the
Ixodes tick, commonly known as the deer tick, as
this vector. In 1982, Burgdorfer et al. were able to
isolate a previously unknown spirochete from the
I. dammini tick. This spirochete is now known to
be the etiologic agent that causes Lyme disease.
Clinically, Lyme disease is similar to other bor-
relial infections, most notably syphilis, in that it
involves multiple organ systems and progresses in
stages. The first report of the maternal-fetal trans-
mission of Lyme disease in 1985 and subsequent
case reports provide evidence that transplacental
passage of the spirochete can result in fetal infec-
tion.3-s Some authors have suggested an increase
in congenital malformations due to Lyme disease;
however, this effect has not been proved conclu-
sively to date. Because of the potential adverse fetal
outcome and possible long-term maternal complica-
tions, it is important to understand the etiology,
diagnosis, and treatment of Lyme disease. Further-
more, it appears that early treatment prevents most
long-term complications in the mother and likely
decreases adverse effects in the fetus.
EPIDEMIOLOGY
The Centers for Disease Control (CDC) reports
that, currently, Lyme disease is the most common
vector-borne disease in the United States, with an
estimated 1,500 cases annually. Although reported
throughout the country, cases have been primarily
clustered in three geographic areas: the Northeast
(Massachusetts to Maryland), the Midwest (Wis-
consin to Minnesota), and the West (Oregon to Cali-
fornia). Overseas, 1,000 new cases per year are re-
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ported from Europe and additional cases are
reported from the Soviet Union, China, Japan, and
Australia.: The disease is usually transmitted during
the warm months, primarily May and June. There
has been a dramatic increase in the number ofLyme
disease cases over the last decade for several rea-
sons: an increase in the deer population, especially
in the East; an influx of people into rural areas
increasing exposure to disease-bearing ticks; and an
increased recognition of Lyme disease by health
care professionals.
Vector
Lyme disease is caused by the spirochete Borrelia
burgdorferi that is transmitted by the Ixodes tick
(more commonly known as the deer tick). These
vectors include L dammini in the Northeast and
Midwest, I. pacificus in the western states, I. ricinus
in Europe, and L persu/catus in Asia. In addition,
Amblyomma americanum (known as the Lone Star
tick) has been identified as a vector in Louisiana
and Texas. During its 2-year life cycle, the Ixodes
tick undergoes 3 stages: larva, nymph, and adult.
The adult female lays thousands of eggs during the
spring which hatch during the late spring and early
summer. The larva feed on the white-footed mouse,
which is almost universally infected with B. burg-
dorferi in the summer months, resulting in transmis-
sion to the larval tick. The larva becomes dormant
in the fall and winter, followed by molting in the
spring which results in a nymph. The nymph then
feeds on the deer mouse or other animals, including
humans. If the nymph is infected with B. burgdor-
feri, vertical transmission (and human infection) can
occur. In the fall, the nymph molts into the adult
tick and attaches to a deer. Mating between adult
ticks occurs, the female lays her eggs, and the cycle
starts over.
Clinical Manifestations
Like other syphilitic diseases, Lyme disease prog-
resses in stages. Asbrink and Hovmark described
3 states that correspond to the time course of disease
progression. Stage I is identified by the characteris-
tic skin lesion of Lyme disease, ECM, and nonspe-
cifi flu-like symptoms with regional lymphadenop-
athy. Weeks to months later, stage II develops with
signs and symptoms of disseminated infection and
multiorgan involvement such as cardiac or neurolog-
ical abnormalities, musculoskeletal symptoms, or
intermittent arthritis. Months to years later, stage
III develops with chronic manifestations of dissem-
inated disease (Table 1). Although this classification
system is useful in describing the course of Lyme
disease, there is much overlap in these stages, mak-
ing a precise classification difficult.
ECM, the hallmark of Lyme disease, is seen in
60-80% of patients. Classically, the lesion starts as
a small erythematous plaque or macule and then
expands to a diameter of approximately 15 cm
(range of 3-68 cm) with an area of centralized clear-
ing.
1 The rash, typically seen on the thigh, groin,
or axilla, may be associated with pruritis or a burning
sensation. The rash lasts 3-4 weeks (range of day
to 14 months). In 50% of patients, multiple lesions
develop. The primary lesion is usually associated
with low-grade fever, flu-like symptoms (migratory
arthralgias, myalgias, and headache), and regional
lymphadenopathy.
11 Within days or weeks, the B.
burgdorferi spirochete may spread to secondary sites
through the patient’s lymph and blood. During this
disseminated (second) stage of Lyme disease, the
neurologic, joint, and cardiovascular systems are pri-
marily affected.
The most common neurologic complication of
Lyme disease is headache, but more severe prob-
lems can occur. Within 4 weeks of exposure, 10-
15% of patients exhibit a triad of ncurologic symp-
toms: meningitis, cerebral-nerve palsy, and
peripheral radiculopathies,
lz The meningitis is char-
acterized by severe headaches with neck stiffness
but without a Kernig’s or Brudzinski’s sign. A spinal
tap typically reveals a lymphocytic pleocytosis
(---100 WBC/mm3) with minimally elevated protein
and normal glucose.z’3 One-half of the cases of
meningitis are associated with a mild encephalitis
with deficits in concentration, lethargy, and emo-
tional lability. Cranial-nerve palsies, most com-
monly involving the facial nerve (Bell’s palsy), may
be seen concurrently with meningitis in as many as
15% of these patients.
3 Other nerve palsies involve
the third and sixth cranial nerves. Also seen are
peripheral and sensory radiculopathies which may
include severe neuritic pain, dysthesias, focal weak-
ness, and areflexia, lz’3
Arthralgias and myalgias are commonly seen
early in the disease. Approximately 60% of un-
treated patients experience brief attacks of asym-
metric, oligoarticular arthritis. The arthritis usually
affects the large joints, especially the knee. In ap-
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TABLE I. Common manifestations of Lyme disease by stage
Early infection Late infection
Localized Disseminated Persistent






















Severe malaise and fatigue
Acrodermatitis chronica atrophicans
Prolonged arthritis attacks, chronic
arthritis
Chronic encephalomyelitis, spastic
paraparesis, ataxic gait, subtle
mental disorders
Chronic fatigue
The stages in this table provide a guideline for the timing of the manifestations of disease; however, the stages can be variable.
proximately 10% of these patients, chronic arthritis
develops, resulting in erosion of the cartilage and
bone and permanent joint disability. Interestingly,
patients with HLA DRz and HLA DR4 are more
likely to be affected by arthritis, suggesting an al-
tered immune response with autoimmune destruc-
tion triggered by the spirochete.
14The synovial fluid
reveals an elevated leukocyte count (range of 2,000-
11,000) and a predominance of polymorphonuclear
leukocytes. Immune complexes are also present,
further suggesting an autoimmune-type phenome-
non that results in joint destruction. 15
In 4-10% of the patients with Lyme disease,
cardiac complications develop 3-6 weeks after the
onset of early symptoms.
16 The hallmark cardiac
lesion is heart block which varies from first degree
to complete. Usually, the conduction deficit is short
lived (1-2 weeks), requiring only temporary pacing,
if any. In a few patients, more diffuse cardiac
involvement is seen, resulting in acute myocarditis,
mild left ventricular dysfunction, and, rarely, cardio-
megaly with fatal pancarditis.
The chronic manifestations of disseminated dis-
ease are well described. Chronic arthritis, which
tends to affect one joint or a few large joints, espe-
cially the knee, can result in destruction of bone
and cartilage and permanent joint disability. Syn-
dromes of the central and peripheral nervous sys-
tems usually involve distal paresthesias or radiculo-
pathy. In addition, subtle symptoms of central
nervous system involvement can be seen with
memory loss, somnolence, and behavioral changes.
The most severe late nervous-system involvement
is a progressive encephalomyelitis with spastic dis-
paresis, bladder dysfunction, ataxia, cranial-nerve
deficits, and dementia. A late skin manifestation of
Lyme disease, acrodermatitis chronica atrophicans,
which has also been well described, can lead to
atrophy of the skin.
PREGNANCY
Since Lyme disease was first described, there has
been concern about the transmission of B. burgdor-
feri across the placenta with adverse fetal effects,
as is seen with other spirochete diseases such as
syphilis and relapsing fever. Isolated cases of the
transplacental passage of B. burgdorferi, the first in
1985 by Schlesinger and colleagues,7 have been
documented. In that case, spirochetes were found
in multiple organ systems in an infant who died
shortly after birth from congenital heart disease.
The mother, who had ECM early in pregnancy, did
not receive antimicrobial therapy. Weber et al. 18
reported a case ofLyme disease in a woman treated
with a subtherapeutic course of penicillin. The
pregnancy progressed to term, but the infant died
within 24 h of birth of respiratory failure, probably
from antenatal brain damage. B. burgdorferi was iso-
lated from the liver and brain of the infant. One
other case of stillbirth in which the spirochete was
isolated from multiple organs has been described. 19
These cases confirm that transplacental passage of
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the spirochete with fetal infection occurs; however,
it is unclear if Lyme disease was the actual cause
of fetal death.
A retrospective review of 19 cases of women
diagnosed with Lyme disease in pregnancy re-
vealed 5 infants with adverse fetal outcomes; how-
ever, none of the outcomes appeared related.2 This
review did not show a teratogenic effect of Lyme
disease on the fetus. Another report of 17 women
who had documented first-trimester infections
showed 2 abnormal pregnancy outcomes: a sponta-
neous abortion and an infant with syndactyly. Nei-
ther case could be attributed to Lyme disease. 21
Three studies were carried out on cord-blood serol-
ogy and the relationship of B. burgdorferi-specific
antibody to the incidence of congenital malforma-
tions. Williams et al. 22 surveyed 463 infants, 282
from an endemic area and 181 from a nonendemic
area, and found no association between the pres-
ence of antibody to B. burgdorferi and congenital
malformations. Likewise, Nadal et al. 23 surveyed
1,416 mother/infant pairs and found a prevalence
of positive serology of approximately 1%. Of these
12 infants, born to a mother who had active Lyme
disease during pregnancy had an isolated ventricu-
loseptal defect. In the 11 infants with elevated cord
IgG titers, 6 had abnormal neonatal courses: 2 with
hyperbilirubinemia, 1 with muscular hypotonia,
small-for-gestational age, 1 with microcephaly, and
with supraventricular tachycardia. All 6 were nor-
mal at 8 months of age. The authors concluded that
there was no association of positive serology with
adverse neonatal outcomes. Strobino et al.24 pro-
spectively studied just over 2,000 women in an en-
demic area and found positive serologies in 7.1%.
As in the 2 previous studies, no correlation was seen
between positive serology and congenital malforma-
tion, although the authors felt the results to be
inconclusive because of the small number of cases.
Furthermore, no increased risk of fetal death or
low birth weight was seen despite the presence of
positive serology.
In summary, while Lyme disease can be trans-
mitted to the fetus, the incidence of transplacental
passage is unknown. Several case reports have asso-
ciated the B. burgdorferi organism with fetal infec-
tion, but this relationship is incompletely under-
stood and fetal infection may be a preventable
outcome with adequate treatment. Large surveys
of women at risk in endemic areas have shown
a low prevalence of seropositivity. In general, the
pregnancy outcome in these women is similar to the
general population. Because of the low incidence of
Lyme disease, even in endemic areas, studies to
date have not conclusively ruled out an adverse
effect of Lyme disease on fetal outcome. For this
reason, close observation ofwomen at risk is recom-
mended.
DIAGNOSIS
The clinical diagnosis of Lyme disease is difficult
because of the multiple manifestations of the dis-
ease and the infrequent recall of a tick bite. ECM,
the hallmark lesion of Lyme disease, may not be
present in 20-40% of patients. Although 3 stages
of disease have been described, they are variable
and overlap in the time of onset. Commercially
available serologic tests can be helpful in establish-
ing the diagnosis. The most commonly used and
widely available tests are the immunofluorescent
assay (IFA) and enzyme-linked immunosorbent
assay (ELISA), with the more sensitive and specific
Western blot used to confirm a positive result, zs-z7
Paired serum samples can be obtained, with a rise
in titer of the assay suggestive of disease, but moni-
toring the antibody titers is required over weeks
to months. More helpful is the detection of IgM
antibodies (usually within 2-4 weeks of exposure),
followed by IgG antibodies (usually 6 weeks after
exposure). The IgG antibody titer will typically rise
higher than the IgM and persist for months or
even years,
z6
One obvious limitation of serologic testing is the
development of signs and symptoms of the disease
prior to development of an antibody response, re-
sulting in a false-negative result. In addition, if anti-
biotic treatment is initiated immediately, an anti-
body response may never develop, rendering
serologic testing useless. Both IFA and ELISA
methods are associated with false-positive results in
the setting of syphilis, juvenile rheumatoid arthritis,
systemic lupus erythematosus, and endocarditis,z5
The sensitivity and specificity of these tests, which
vary widely from laboratory to laboratory, are de-
pendent on when the test is obtained in relation to
acquisition of the infection,z8 A further complication
is the presence of the IgG antibody for months
or years after an infection, making it difficult to
determine if the current infection is primary or sec-
ondary. The Western blot assay, which is more sen-
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Amoxicillin, 500 mg p.o.g.i.d, for 10 days (extended to 30 days with persistent symptoms)
PCN allergy: erythromycin, g orally/day in divided doses for 10-30 days
Penicillin G, 200,000-300,000 units/kg/day (up to 20 million units/day) IV for 10 days or
Ceftriaxone, 2 g/day for 10 days




Same as ECM (may require 7-8 weeks of therapy for persistent symptoms)
Amoxicillin and probenecid, 500 mg each orally g.i.d, for 30 days or
Ceftriaxone, 2 g IV daily for 14 days or
Penicillin G, 300,000 units q 4 h IV for 14 days
aAdapted from Steere.
sitive and specific than the IFA or ELISA, is cur-
rently used as a confirmatory test in many
laboratories. As with the IFA and ELISA, the West-
ern blot results vary widely between laboratories,
with no standardization of results. The CDC is ex-
pected to issue a set of standardization guidelines
soon. Because of the limitations of serologic testing,
the current recommendation is to diagnose Lyme
disease based on clinical and epidemiologic criteria
and use serologic tests as adjuncts to the diagnosis.
PREVENTION AND TREATMENT
It has been well documented that the early treat-
ment of Lyme disease greatly reduces the later
manifestations of disseminated infection, zg-sz The
prevention of Lyme disease involves avoiding tick-
infested areas, wearing appropriate clothing, and
using proper insect repellent.
33 Examining the body
for ticks and promptly removing them are im-
portant. Saving the tick may be useful for later
identification. Future preventive measures may in-
clude a vaccine that is currently being studied.
Table 2 lists the treatment regimens for Lyme
disease in pregnancy. Several caveats are important
to consider in treating Lyme disease during preg-
nancy. While effective in treating Lyme disease
and recommended as first-line treatment in non-
pregnant patients, doxycycline is contraindicated in
pregnancy and not included in Table 2. IV ceftriax-
one, once daily, can be used as first-line therapy in
a patient with neurologic symptoms or in a patient
with difficulty in taking oral penicillin (which usu-
ally requires 6 divided doses/day). In a penicillin-
allergic patient, chloramphenicol for 14 days is ef-
fective. The recommended duration oftherapy may
not be adequate for stage III joint or neurologic
disease. A Jarisch-Herxheimer reaction, which may
result in significant hypotension and fever, has
been described.
CONCLUSIONS
As the prevalence of Lyme disease has increased,
the concern has grown about the effect of Lyme
disease on the fetus of an infected mother. As dis-
cussed in this review, cases have been reported of
transplacental passage of the spirochete, resulting
in fetal infection and possibly death. However, the
incidence of transplacental passage ofLyme disease
and the actual risk ofneonatal morbidity and mortal-
ity are currently unknown. Clearly, the early recog-
nition and treatment of patients with Lyme disease
decrease the risks of long-term complications, but
the benefit to the fetus of early maternal treatment
is unknown. Although serology is helpful after the
first 3-4 weeks of infection, a clinical suspicion of
disease and the recognition of signs and symptoms
are the most important tools in establishing an early
diagnosis. There is not enough information avail-
able to recommend specific fetal evaluation or inter-
vention ifthe mother is infected with Lyme disease.
The current recommendations emphasize close ex-
amination of the newborn for signs of intrapartum
infection.
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